IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
- Conditions
- Acromegaly
- Interventions
- Behavioral: Home administration
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 59
- Registration Number
- NCT00447499
- Locations
- 🇺🇸
Research Institute of Dallas, Dallas, Texas, United States
🇺🇸Northwestern University The Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 38
- Registration Number
- NCT00444873
- Locations
- 🇩🇪
Klinikum Innenstadt, Munich, Germany
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 25
- Registration Number
- NCT00444639
- Locations
- 🇳🇱
AMC Amsterdam, Amsterdam, Netherlands
🇳🇱Diaconessenhuis Leiden, Leiden, Netherlands
🇳🇱Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 100
- Registration Number
- NCT00415246
- Locations
- 🇧🇪
ULB Erasme, Bruxelles, Belgium
🇫🇷Hôpital Claude Huriez, Lille, France
🇫🇷CHU Hôpital Salvator, Marseille, France
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 125
- Registration Number
- NCT00383708
- Locations
- 🇩🇪
Charite Campus Mitte, Berlin, Germany
🇫🇷CHU de Rangueil, Toulouse, France
🇮🇹University Federico II, Napoli, Italy
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
- Conditions
- Endocrine Tumors
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 264
- Registration Number
- NCT00353496
- Locations
- 🇺🇸
Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸The John Hopkins Hospital, Baltimore, Maryland, United States
Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children
- Conditions
- Diarrhoea
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 300
- Registration Number
- NCT00352716
- Locations
- 🇵🇪
Hospital Regional de Ica, Ica, Peru
🇵🇪Hospital Nacional Daniel Alcides Carrión, San Miguel, Peru
🇵🇪Clinica San Pablo Sede Norte, Lima, Peru
Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children
- Conditions
- Diarrhoea
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 302
- Registration Number
- NCT00352989
- Locations
- 🇲🇾
Kulim Hospital, Jalan Mahang, Kedah, Malaysia
🇲🇾Serdang Hospital, Selangor, Malaysia
🇲🇾Ipoh Hospital, Ipoh - Perak, Malaysia
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
- Conditions
- Growth Disorders
- Interventions
- Drug: rh IGF-1 (mecasermin)
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 114
- Registration Number
- NCT00330668
- Locations
- 🇫🇷
Ipsen, Paris, France
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT00326469
- Locations
- 🇪🇸
H. General de Elche, Elche, Spain
🇪🇸H. Germans Trias i Pujol, Badalona, Spain
🇪🇸H. Ramón y Cajal, Madrid, Spain